Pioglitazone in Clinical Practice: Where Are We Now?
Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone an...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare Communications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508118/ https://www.ncbi.nlm.nih.gov/pubmed/22373598 http://dx.doi.org/10.1007/s13300-012-0001-z |
_version_ | 1782251182386839552 |
---|---|
author | Govindan, Joytish Evans, Marc |
author_facet | Govindan, Joytish Evans, Marc |
author_sort | Govindan, Joytish |
collection | PubMed |
description | Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk–benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk–benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence. |
format | Online Article Text |
id | pubmed-3508118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer Healthcare Communications |
record_format | MEDLINE/PubMed |
spelling | pubmed-35081182012-11-28 Pioglitazone in Clinical Practice: Where Are We Now? Govindan, Joytish Evans, Marc Diabetes Ther Review Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk–benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk–benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence. Springer Healthcare Communications 2012-02-29 2012-12 /pmc/articles/PMC3508118/ /pubmed/22373598 http://dx.doi.org/10.1007/s13300-012-0001-z Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Review Govindan, Joytish Evans, Marc Pioglitazone in Clinical Practice: Where Are We Now? |
title | Pioglitazone in Clinical Practice: Where Are We Now? |
title_full | Pioglitazone in Clinical Practice: Where Are We Now? |
title_fullStr | Pioglitazone in Clinical Practice: Where Are We Now? |
title_full_unstemmed | Pioglitazone in Clinical Practice: Where Are We Now? |
title_short | Pioglitazone in Clinical Practice: Where Are We Now? |
title_sort | pioglitazone in clinical practice: where are we now? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508118/ https://www.ncbi.nlm.nih.gov/pubmed/22373598 http://dx.doi.org/10.1007/s13300-012-0001-z |
work_keys_str_mv | AT govindanjoytish pioglitazoneinclinicalpracticewherearewenow AT evansmarc pioglitazoneinclinicalpracticewherearewenow |